Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Total Current Liabilities (2020 - 2025)

Historic Total Current Liabilities for Relay Therapeutics (RLAY) over the last 6 years, with Q3 2025 value amounting to $32.6 million.

  • Relay Therapeutics' Total Current Liabilities fell 3058.04% to $32.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $32.6 million, marking a year-over-year decrease of 3058.04%. This contributed to the annual value of $50.7 million for FY2024, which is 6759.39% up from last year.
  • As of Q3 2025, Relay Therapeutics' Total Current Liabilities stood at $32.6 million, which was down 3058.04% from $32.5 million recorded in Q2 2025.
  • Over the past 5 years, Relay Therapeutics' Total Current Liabilities peaked at $71.6 million during Q2 2023, and registered a low of $16.1 million during Q1 2021.
  • Over the past 5 years, Relay Therapeutics' median Total Current Liabilities value was $41.7 million (recorded in 2022), while the average stood at $43.2 million.
  • As far as peak fluctuations go, Relay Therapeutics' Total Current Liabilities surged by 16195.06% in 2022, and later crashed by 5248.87% in 2023.
  • Relay Therapeutics' Total Current Liabilities (Quarter) stood at $24.3 million in 2021, then skyrocketed by 161.95% to $63.7 million in 2022, then tumbled by 52.49% to $30.3 million in 2023, then surged by 67.59% to $50.7 million in 2024, then crashed by 35.73% to $32.6 million in 2025.
  • Its Total Current Liabilities stands at $32.6 million for Q3 2025, versus $32.5 million for Q2 2025 and $37.1 million for Q1 2025.